Zyla Life Sciences logo

ZCOR - Zyla Life Sciences Share Price

$2.3 0.0  0.0%

Last Trade - 15/01/20

Sector
Healthcare
Size
Micro Cap
Market Cap £16.6m
Enterprise Value £81.9m
Revenue £54.2m
Position in Universe 5202nd / 6415
Bullish
Bearish
Unlock ZCOR Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

ZCOR Revenue Unlock ZCOR Revenue

Net Income

ZCOR Net Income Unlock ZCOR Revenue

Normalised EPS

ZCOR Normalised EPS Unlock ZCOR Revenue

PE Ratio Range

ZCOR PE Ratio Range Unlock ZCOR Revenue

Dividend Yield Range

ZCOR Dividend Yield Range Unlock ZCOR Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ZCOR EPS Forecasts Unlock ZCOR Revenue
Profile Summary

Zyla Life Sciences, formerly Egalet Corporation, is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and commercializing treatments for pain and other conditions. The Company's products include OXAYDO and SPRIX Nasal Spray. The Company is developing two late-stage product candidates, ARYMO ER and Egalet-002 using Guardian Technology. The Company's product SPRIX Nasal Spray, which contains ketorolac tromethamine is a non-steroidal anti-inflammatory drug (NSAID) indicated in adult patients for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level. The Company's product OXAYDO is an approved immediate-release (IR) oxycodone product formulated to deter abuse through snorting. Its product candidate, ARYMO ER is an abuse-deterrent (AD), extended-release (ER), oral morphine formulation. The Company's product candidate, Egalet-002, is an abuse-deterrent, extended-release, oral oxycodone formulation.

Directors
Last Annual December 31st, 2018
Last Interim September 30th, 2019
Incorporated August 21, 2013
Public Since February 6, 2014
No. of Shareholders: 2
No. of Employees: 131
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange OTC Markets Group
Shares in Issue 9,360,968
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ZCOR Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ZCOR
Upcoming Events for ZCOR
Similar to ZCOR
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.